SCHEMBL27057162

SCHEMBL27057162

COc1cc2c(Cl)nc(C)nc2cc1OCCCOC=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP1 P22413 3/20 0.46
▸ TNF P01375 2/20 0.41
▸ PDE4A P27815 3/20 0.39
▸ PDE4D Q08499 3/20 0.39
▸ EHMT2 Q96KQ7 2/20 0.38
▸ KLK7 P49862 1/20 0.38
▸ KLK14 Q9P0G3 1/20 0.38
▸ KLK5 Q9Y337 1/20 0.38
▸ KRAS P01116 3/20 0.37
▸ SOS1 Q07889 3/20 0.37
▸ EGFR P00533 1/20 0.37
▸ PDE3B Q13370 2/20 0.36
▸ PDE3A Q14432 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29723105 0.80 PDE4A (0.54) ENPP1PDE4APDE4DKRASSOS1
SCHEMBL372259 0.80 PDE4A (0.54) ENPP1PDE4APDE4DKRASSOS1
SCHEMBL27057125 0.79 ENPP1 (0.49) ENPP1TNFPDE4APDE4DEGFR
SCHEMBL27041271 0.78 TNF (0.51) ENPP1TNFEGFRHDAC3KDR
SCHEMBL27057148 0.78 ENPP1 (0.57) ENPP1TNFPDE4APDE4DEHMT2
SCHEMBL27057164 0.78 TRPV1 (0.48) PDE3BPDE3ANPC1MAPTHPGD
SCHEMBL27041258 0.74 ENPP1 (0.42) ENPP1TNFPDE4APDE4DEHMT2
SCHEMBL6118947 0.74 SRC (0.55) EGFRMAPTKDR
SCHEMBL20509231 0.74 ELANE (0.55) ENPP1EHMT2KRASSOS1EGFR
SCHEMBL27882455 0.73 ENPP1 (0.55) ENPP1TNFPDE4APDE4DKLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025863-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2024-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025863-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS SOS1, SOS2, SOST ENPP1 1234/4885TNF 3775/4885PDE4A 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback